EGFR and non-small cell lung carcinoma: In the case of non-small-cell lung cancer (NSCLC), gefitinib, a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR), has been used clinically to treat patients with the EGFR mutation.